Gardent Pharmaceuticals signs agreement to be acquired by Switch Pharma .

NEW YORK, 25, August, 2006 -- Gardant Pharmaceuticals, Inc. (Other OTC:GRDP.PK)
Gardent Pharmaceuticals today announced it has signed an agreement to be
acquired by Switch Pharma Ltd..Shares of Switch Pharma Ltd., which is currently
in the process of going public in London, will be issued to acquire Gardant
Pharmaceuticals. Pursuant to the agreement, the Switch Pharma Ltd. shares issued
in the transaction must be trading for at least $1.38 per share when the shares
of Switch Pharma Ltd. commence trading publicly in London. Shareholders of
Gardent will receive one share of Switch Pharma for every Gardent share
owned.The transaction is expected to close on September 30th subject to
requisitie approvals.

Switch Pharma is a company that is focused on the development and
commercialization of proprietary, innovative and differentiated therapeutic drug
products. The Company's core strategy is to focus on the uses of different
applications for known drugs. The Company's management believe's that this
method allows Switch Pharma to be selective about the drugs it develops and
gives the Company the advantage of already knowing the safety and toxicology
profiles of known drugs before identifying new indications, thereby saving
considerable expense and time. The existing therapeutic drugs have typically
been marketed for a number of years, have established safety profiles and can be
developed for new clinical indications. Utilizing this development focus, the
Company seeks to reduce the risk, time and cost of new product development as
compared to the development of new chemical entities. Gardant Pharmaceuticals
was attractive to Switch Pharma because of its risk balanced portfolio and the
fact that the majority of the portfolio now consists of Oncology-focused
compounds, as Oncology applications and therapeutics is the intended focus of
Switch Pharma going forward. Of the eight re-purposed therapeutic products that
Switch currently is seeking to develop, two are for the Oncology marketplace.


Gardant Pharmaceuticals previously announced the spin-off to its shareholders of
record on July 31, 2006 of its shares of Genaderm, Inc., Avantogen Oncology,
Inc. (f/k/a Innovate Oncology, Inc.), and Amilar Pharmaceuticals Inc. Those
spin-offs will proceed as planned, subject to receipt of requisite approvals.
Gardant previously announced the spin-off of its shares of Accura Pharma PLC to
shareholders of record as of April 21, 2006. Gardant has been advised that
Accura Pharma PLC anticipates that its common shares will commence trading in
London during the week of September 12, 2006.

About Gardant Pharmaceuticals, Inc.
Gardant Pharmaceuticals, Inc., after spinning-off certain subsidiaries, is
focused on developing a portfolio of compounds which have an emphasis on
treating cancer. The Company is focused on developing and commercializing novel
pharmaceutical compounds in an efficient, cost-effective way. Gardant seeks to
use its academic, industry and capital market relationships to expedite drug
development and raise capital to create and fund compounds. Gardant's strategy
relies on its development network for research, clinical development and project
management to guide early-stage compounds from the discovery process through to
Phase II/III development where incremental value can be created. Gardant
Pharmaceuticals, Inc. Safe Harbor Statement Certain statements contained herein
are "forward-looking" statements (as such term is defined in the Private
Securities Litigation Reform Act of 1995). Because these statements include
risks and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically, factors
that could cause actual results to differ materially from those expressed or
implied by such forward-looking statements include, but are not limited to: the
ability of Gardant to finance its activities on commercially acceptable terms,
in timely fashion, or at all; risks associated with pre-clinical and clinical
developments in the biopharmaceutical industry in general and in Gardant's
compounds under development in particular; the potential failure of Gardant's
compounds under development to prove safe and effective for treatment of
disease; uncertainties inherent in the early stage of Gardant's compounds under
development; failure to successfully implement or complete clinical trials;
failure to receive marketing clearance from regulatory agencies for our
compounds under development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Gardant's business, structure or projections;
the development of competing products; uncertainties related to Gardant's
dependence on third parties and partners; and those risks described in the
filings with the SEC, all of which are under Gardant's prior name as Mobile
Design Concepts, Inc. Gardant disclaims any obligation to update these
forward-looking statements.

Contact:
         Gardant Pharmaceuticals, Inc.
         Charlotte Ramelli
         (212) 897-6849